Australian Government
Department of Health
Therapeutic Goods Administration

Advisory Committee on Vaccines

Meeting Statement 23 – Friday 30 July 2021

Section A: Submissions for registration

The committee provided advice on one application to register a new vaccine, and one application to extend the indications of the vaccine.

Further details of the ACV discussion and advice associated with these pre-market items may be released within the Australian Public Assessment Report (AusPAR). Please note that there is a delay between when an application is considered by the ACV and the publication of the AusPAR. To browse all AusPARs see AusPAR search.

Section B: Safety

The committee provided advice on one matter relating to pharmacovigilance.

COVID-19 vaccine AstraZeneca [now, Vaxzevria] and Guillain Barre Syndrome

The ACV provided advice on the strength of evidence for the risk of Guillain Barre Syndrome (GBS) following COVID-19 vaccine AstraZeneca.

The ACV advised that GBS should be added to the Product Information (PI) of this vaccine as a warning.

The ACV advised that information for consumers could include wording such as 'greater than expected', with an explanation that there is a background rate of GBS in the absence of vaccination. A simple tabulation of expected and observed cases could be useful.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines or contact the ACV by email ACV@health.gov.au.